BUZZ-Australia's Argent BioPharma rises most in over 3 months on premium capital raising

** Shares of Argent BioPharma RGT.AX rise as much as 52.9% to A$0.260, their biggest intraday pct gain since Oct 1, 2024

** The clinical-stage biopharma co completes $4.5 mln capital raise at $0.40 per share

** Issue price represents a premium of 276.5%, compared with stock's last closing price of A$0.17

** Says placement will help advance co's drug development pipeline, with focus on clinical studies for CannEpil - a seizure-control treatment  for refractory epilepsy and cerebral palsy

** Stock hits its highest level since Dec 2

** About 231,485 shares change hands, 13.2 times the 30-day average volume of 17,562

** Stock fell 64.2% in 2024

(Reporting by Manasi Dasa Sundeep in Bengaluru)

((Manasi.DasaSundeep@ThomsonReuters.com))